ArticleActa pharmacologica Sinica2019

Plasma miR-142 predicts major adverse cardiovascular events as an intermediate biomarker of dual antiplatelet therapy.

Qian-Jie Tang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.